✨ Your Portfolio is fetched and updated from zerodha.

Astrazeneca Pharma India Ltd.

ASTRAZEN

Market Cap
₹18,757 Cr.
P/E
228.97

Astrazeneca Pharma India Ltd.

  • Astrazeneca Pharma I
  • Alembic Pharma
  • Eris Lifesciences
  • TJI Pharma - Small Cap
FAQs on Astrazeneca Pharma India Ltd. Shareprice

Astrazeneca Pharma I has given better returns compared to its competitors.
Astrazeneca Pharma I has grown at ~32.39% over the last 7yrs while peers have grown at a median rate of 7.25%

Yes, Astrazeneca Pharma I is expensive.
Latest PE of Astrazeneca Pharma I is 228, while 3 year average PE is 112.
Also latest EV/EBITDA of Astrazeneca Pharma I is 117 while 3yr average is 72.82.

View FAQ's On Business
Growth Table
  • Astrazeneca Pharma India Ltd.
  • Alembic Pharma
  • Eris Lifesciences
Balance Sheet
  • Astrazeneca Pharma India Ltd.
  • Alembic Pharma
  • Eris Lifesciences
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Astrazeneca Pharma India Ltd.
  • Alembic Pharma
  • Eris Lifesciences
Cash Flow
  • Astrazeneca Pharma India Ltd.
  • Alembic Pharma
  • Eris Lifesciences
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Astrazeneca Pharma India Ltd.
  • Alembic Pharma
  • Eris Lifesciences
Quarterly Results
  • Astrazeneca Pharma India Ltd.
  • Alembic Pharma
  • Eris Lifesciences
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Rhapson method.
Learn how to use Reverse DCF
FAQs on Astrazeneca Pharma India Ltd. Financials

Balance sheet of Astrazeneca Pharma I is strong.
It shouldn't have solvency or liquidity issues.

Yes, The debt of Astrazeneca Pharma I is increasing.
Latest debt of Astrazeneca Pharma I is -₹496.78 Crs as of Sep-24.
This is greater than Mar-24 when it was -₹1,011.68 Crs.

The profit is oscillating.
The profit of Astrazeneca Pharma I is ₹81.92 Crs for TTM, ₹162 Crs for Mar 2024 and ₹99.29 Crs for Mar 2023.

The company seems to pay a good stable dividend.
Astrazeneca Pharma I latest dividend payout ratio is 37.15% and 3yr average dividend payout ratio is 39.34%

Companies resources are allocated to majorly unproductive assets like Accounts Receivable

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech